Table 1.
Characteristics of men aged 50 to 74 years with prostate cancer in the National Prostate Cancer Register of Sweden, 2000 to 2009*
| Characteristic | County Incidence | ||
|---|---|---|---|
| High (n = 33780) | Intermediate (n = 37624) | Low (n = 16377) | |
| Age at diagnosis, y | |||
| Median (IQR) | 70 (63–77) | 70 (63–77) | 72 (65–79) |
| Mean (SD) | 70.0 (9.3) | 70.2 (9.2) | 71.7 (9.1) |
| Serum PSA level, ng/mL | |||
| Median (IQR) | 10.8 (6.0–27.0) | 12.0 (6.6–32.0) | 15.0 (7.6–43.0) |
| No. missing (%) | 506 (1.5) | 1114 (3.0) | 385 (2.4) |
| Mode of detection, No. (%) | |||
| PSA testing as a part of health check-up | 10684 (31.6) | 10101 (26.8) | 3646 (22.3) |
| Lower urinary tract symptoms | 10533 (31.2) | 10668 (28.4) | 5793 (35.4) |
| Other symptoms/unknown | 12563 (37.2) | 16855 (44.8) | 6938 (42.4) |
| Planned treatment, No. (%)† | |||
| Surveillance | 8937 (26.5) | 8613 (22.9) | 4079 (24.9) |
| Radical prostatectomy | 8444 (25.0) | 8425 (22.4) | 2419 (14.8) |
| Radiation therapy | 4198 (12.4) | 4891 (13.0) | 2501 (15.3) |
| Hormonal therapy | 10931 (32.4) | 12600 (33.5) | 6620 (40.4) |
| Other/missing | 1270 (3.8) | 3095 (8.2) | 758 (4.6) |
| Risk category, No. (%)‡ | |||
| Low risk | 9874 (29.2) | 9593 (25.5) | 3366 (20.6) |
| Intermediate risk | 8651 (25.6) | 8997 (23.9) | 3867 (23.6) |
| High risk | 7908 (23.4) | 9917 (26.4) | 4570 (27.9) |
| Regionally metastatic | 2097 (6.2) | 2735 (7.3) | 1407 (8.6) |
| Distant metastases | 4524 (13.4) | 5158 (13.7) | 2891 (17.7) |
| Missing | 726 (2.1) | 1224 (3.3) | 276 (1.7) |
* IQR = interquartile range; PSA = prostate-specific antigen; SD = standard deviation.
† Initiated or planned within the 6 months after diagnosis.
‡ Risk groups according to modification of the National Comprehensive Cancer Network. Low risk: T1 to 2, Gleason score 2 to 6, and PSA < 10ng/mL. Intermediate risk: T1 to 2, Gleason score 7, and/or PSA 10 to <20ng/mL. High risk: T3, and/or Gleason score 8 to 10, and/or PSA 20 to <50ng/mL. Regionally metastatic disease: T4 and/or N1 and/or PSA 50 to <100ng/mL in the absence of distant metastases (M0 or Mx). Distant metastases: M1 and/or PSA ≥100ng/mL.